SKYE · Skye Bioscience, Inc. · Executive Compensation
$1.02
-0.01 (-1.36%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q4 2025 earnings call transcript
Going-concern doubt
— flagged Nov 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed Nov 13, 2026
Market Cap
$4.56M
Shares
4.42M
Volume · Nov 19
12.7K
Avg daily vol (62 sessions)
84.15K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Punit Dhillon | Chief Executive Officer | $1,361,831 |
| Kaitlyn Arsenault | Former Chief Financial Officer | $888,589 |
| Tu Diep | Chief Operating Officer | $875,939 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Punit Dhillon | Chief Executive Officer | $6,139,625 |
| Kaitlyn Arsenault | Chief Financial Officer | $2,266,825 |
| Tu Diep | Chief Operating Officer | $2,207,168 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Punit Dhillon | Chief Executive Officer | $1,807,338 |
| Kaitlyn Arsenault | Chief Financial Officer | $1,270,290 |
| Tu Diep | Chief Operating Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Punit Dhillon | CEO | $668,481 |
| Kaitlyn Arsenault | Chief Financial Officer | $469,087 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Punit Dhillon | principal financial and accounting officer | Appointed | 2026-09-11 |
|
John P. Sharp
“Mr. Sharp’s departure is not the result of any disagreement with the Company’s independent auditors or the Company on any matter relating to the Company’s financial statements, internal control over financial reporting, operations, policies or practices.”
|
Chief Financial Officer and principal financial and accounting officer | Resigned | 2026-09-11 |
| Dr. Cliff Jones | Chief Technical Officer | Appointed | 2026-08-14 |
| Dr. Mei-Lun Wang | Chief Medical Officer | Appointed | 2026-08-14 |
| Dr. Caroline Phillips | Chief Scientific Officer | Appointed | 2026-08-14 |
| Peter Collum | Chief Financial Officer | Appointed | 2026-08-14 |
| Lisa Anson | Chief Executive Officer | Appointed | 2026-08-14 |
| Tu Diep | executive officer | Resigned | 2026-08-14 |
| Punit Dhillon | Chief Executive Officer | Resigned | 2026-08-14 |
| John P. Sharp | Chief Financial Officer | Appointed | 2026-04-03 |
| Punit Dhillon | principal accounting officer | Appointed | 2026-02-20 |
| Paul Grayson | Chairman of the Board | Appointed | 2024-10-29 |
| Puneet S. Arora, MD, MS, FACE | Chief Medical Officer | Appointed | 2024-09-04 |
|
Keith Ward, PhD
“Dr. Ward and Dr. Tyle's decision to resign from the Board is not as a result of any disagreement with the Company concerning any matter relating to its operations, policies or practices.”
|
member of the Board | Resigned | 2024-07-03 |
|
Praveen Tyle, PhD
“Dr. Ward and Dr. Tyle's decision to resign from the Board is not as a result of any disagreement with the Company concerning any matter relating to its operations, policies or practices.”
|
member of the Board | Resigned | 2024-07-03 |
| Karen L. Smith MD, PhD, MBA, LLM | director | Appointed | 2024-07-03 |
|
Margaret Dalesandro
“Dr. Dalesandro’s decision to resign from the Board is not as a result of any disagreement with the Company concerning any matter relating to its operations, policies or practices.”
|
member of the Board | Resigned | 2024-03-04 |
| Annalisa Jenkins | director | Appointed | 2024-03-04 |
| Paul Grayson | Venture Partner, Versant & CEO, Tentarix | Appointed | 2023-08-21 |
| Andy Schwab | Managing Partner, 5AM Ventures | Appointed | 2023-08-21 |
| Paul Grayson | Board | Appointed | 2023-08-21 |
| Andrew Schwab | Board | Appointed | 2023-08-21 |
| Dr. Deborah Charych, Ph.D. | director | Appointed | 2023-02-16 |
|
Bobby Rai
“Mr. Rai's resignation as a director was to focus on other commitments and is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
member of the Board of Directors | Resigned | 2023-02-16 |
| Bobby Rai | member of the Nominating and Corporate Governance Committee of the Board | Appointed | 2023-01-06 |
Leadership
- Lisa Anson CEO
- Punit Dhillon CEO, Chief Accounting Officer, Board Member
- Paul Grayson Chairman, Board Member
- Elena Traistaru CFO
- Kaitlyn Arsenault CFO
- Peter Collum CFO
- Tu Diep COO
- Dr. Cliff Jones CTO
- Andrew J. Schwab Board Member
- Andrew Schwab Board Member
- Andy Schwab Board Member
- Annalisa Jenkins Board Member
- Annalisa Jenkins, M.B.B.S., F.R.C.P. Board Member
- Bobby Rai Board Member
- Deborah Charych Board Member
- Dr. Deborah Charych, Ph.D. Board Member
- Karen L. Smith MD, PhD, MBA, LLM Board Member
- Karen Smith Board Member
- Keith Ward Board Member
- Praveen Tyle Board Member
Key facts
CIK
1516551
CUSIP
83086J309
13F (30d)
32 filings
29 filers
Visit website
Investor relations